BRPI0814797A2 - Inibidores dna-pk - Google Patents

Inibidores dna-pk

Info

Publication number: BRPI0814797A2
Authority: BR; Brazil
Prior art keywords: inhibitors; dna
Prior art date: 2007-07-19

Application number

BRPI0814797-3A2A

Other languages

English (en)

Inventor

Mark Frigerio

Marc Geoffrey Hummersone

Keith Allan Menear

Christine Sarah Bailey

Heather Mary Ellen Duggan

Sylvie Gomez

Niall Morrison Barr Martin

Original Assignee

Kudos Pharm Ltd

Cancer Rec Tech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-19

Filing date

2008-07-18

Publication date

2015-02-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814797(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-18 Application filed by Kudos Pharm Ltd, Cancer Rec Tech Ltd filed Critical Kudos Pharm Ltd

2015-02-03 Publication of BRPI0814797A2 publication Critical patent/BRPI0814797A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

BRPI0814797-3A2A 2007-07-19 2008-07-18 Inibidores dna-pk BRPI0814797A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US95063107P	2007-07-19	2007-07-19
US3656008P	2008-03-14	2008-03-14
PCT/GB2008/002459 WO2009010761A1 (en)	2007-07-19	2008-07-18	Dna pk inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0814797A2 true BRPI0814797A2 (pt)	2015-02-03

Family

ID=39791057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814797-3A2A BRPI0814797A2 (pt)	2007-07-19	2008-07-18	Inibidores dna-pk

Country Status (14)

Country	Link
US (1)	US20090042865A1 (pt)
EP (1)	EP2176254A1 (pt)
JP (1)	JP2010533694A (pt)
KR (1)	KR20100063701A (pt)
CN (1)	CN101754964A (pt)
AR (1)	AR067613A1 (pt)
AU (1)	AU2008277418A1 (pt)
BR (1)	BRPI0814797A2 (pt)
CA (1)	CA2693926A1 (pt)
CL (1)	CL2008002130A1 (pt)
RU (1)	RU2009149210A (pt)
TW (1)	TW200918528A (pt)
UY (1)	UY31232A1 (pt)
WO (1)	WO2009010761A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119865D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
EP1654257B1 (en) *	2003-08-13	2010-03-17	Kudos Pharmaceuticals Limited	Aminopyrones and their use as atm inhibitors
EP1794151A1 (en) *	2004-09-20	2007-06-13	Kudos Pharmaceuticals Limited	Dna-pk inhibitors
US7642254B2 (en) *	2005-02-09	2010-01-05	Kudos Pharmaceuticals Limited	ATM inhibitors
AR053358A1 (es) *	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009014910A2 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
WO2011041154A1 (en)	2009-10-01	2011-04-07	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011137428A1 (en) *	2010-04-30	2011-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods of treating hiv infection: inhibition of dna dependent protein kinase
CN109674753A (zh)	2010-06-23	2019-04-26	希玛贝治疗股份有限公司	固态分散体
RS61664B1 (sr)	2012-04-24	2021-04-29	Vertex Pharma	Inhibitori dna-pk
HUE057527T2 (hu)	2013-03-12	2022-05-28	Vertex Pharma	DNS-PK inhibitorok
CN104892589A (zh) *	2014-03-07	2015-09-09	中国科学院上海药物研究所	一类杂环化合物、其制备方法和用途
WO2018026890A1 (en)	2016-08-03	2018-02-08	Cymabay Therapeutics	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
JP2019529475A (ja)	2016-09-27	2019-10-17	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
CN111053903A (zh) *	2019-12-26	2020-04-24	深圳市纳诺艾医疗科技有限公司	一种携带共振原子的核酸类似物的化合物的应用
WO2022148354A1 (zh) *	2021-01-05	2022-07-14	山东轩竹医药科技有限公司	多环类激酶抑制剂
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025217307A1 (en)	2024-04-09	2025-10-16	Revolution Medicines, Inc.	Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0753725B2 (ja) *	1987-10-08	1995-06-07	富山化学工業株式会社	４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) *	1988-10-28	1994-02-08	Hoechst Aktiengesellschaft	Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) *	1988-12-21	1997-12-30	Pharmacia & Upjohn Company	Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5252735A (en) *	1990-06-29	1993-10-12	The Upjohn Company	Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5302613A (en) *	1990-06-29	1994-04-12	The Upjohn Company	Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
AU698990B2 (en) *	1993-04-09	1998-11-19	Toyama Chemical Co. Ltd.	Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5733920A (en) *	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
JP4103968B2 (ja) *	1996-09-18	2008-06-18	株式会社半導体エネルギー研究所	絶縁ゲイト型半導体装置
US6348311B1 (en) *	1999-02-10	2002-02-19	St. Jude Childre's Research Hospital	ATM kinase modulation for screening and therapies
US6387640B1 (en) *	1999-02-10	2002-05-14	St. Jude Children's Research Hospital	ATM kinase modulation for screening and therapies
US6333180B1 (en) *	1999-12-21	2001-12-25	International Flavors & Fragrances Inc.	Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
HUP0301802A3 (en) *	2000-06-28	2009-04-28	Teva Pharma	Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
GB0119863D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119865D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US7049313B2 (en) *	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
DE60335359D1 (de) *	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
EP1654257B1 (en) *	2003-08-13	2010-03-17	Kudos Pharmaceuticals Limited	Aminopyrones and their use as atm inhibitors
EP1794151A1 (en) *	2004-09-20	2007-06-13	Kudos Pharmaceuticals Limited	Dna-pk inhibitors
US7642254B2 (en) *	2005-02-09	2010-01-05	Kudos Pharmaceuticals Limited	ATM inhibitors
AR053358A1 (es) *	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
JP5781720B2 (ja) *	2008-12-15	2015-09-24	ルネサスエレクトロニクス株式会社	半導体装置及び半導体装置の製造方法

2008
- 2008-07-17 UY UY31232A patent/UY31232A1/es not_active Application Discontinuation
- 2008-07-18 EP EP08775986A patent/EP2176254A1/en not_active Withdrawn
- 2008-07-18 CL CL2008002130A patent/CL2008002130A1/es unknown
- 2008-07-18 AU AU2008277418A patent/AU2008277418A1/en not_active Abandoned
- 2008-07-18 TW TW097127524A patent/TW200918528A/zh unknown
- 2008-07-18 CN CN200880024849A patent/CN101754964A/zh active Pending
- 2008-07-18 AR ARP080103124A patent/AR067613A1/es unknown
- 2008-07-18 CA CA2693926A patent/CA2693926A1/en not_active Abandoned
- 2008-07-18 WO PCT/GB2008/002459 patent/WO2009010761A1/en not_active Ceased
- 2008-07-18 BR BRPI0814797-3A2A patent/BRPI0814797A2/pt not_active Application Discontinuation
- 2008-07-18 US US12/175,542 patent/US20090042865A1/en not_active Abandoned
- 2008-07-18 JP JP2010516580A patent/JP2010533694A/ja not_active Withdrawn
- 2008-07-18 RU RU2009149210/04A patent/RU2009149210A/ru not_active Application Discontinuation
- 2008-07-18 KR KR1020107003763A patent/KR20100063701A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
TW200918528A (en)	2009-05-01
EP2176254A1 (en)	2010-04-21
AU2008277418A1 (en)	2009-01-22
US20090042865A1 (en)	2009-02-12
CL2008002130A1 (es)	2009-01-02
JP2010533694A (ja)	2010-10-28
CA2693926A1 (en)	2009-01-22
CN101754964A (zh)	2010-06-23
UY31232A1 (es)	2009-03-02
AR067613A1 (es)	2009-10-14
WO2009010761A1 (en)	2009-01-22
RU2009149210A (ru)	2011-08-27
KR20100063701A (ko)	2010-06-11

Publication	Publication Date	Title
CY2020023I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
CY2017016I1 (el)	2017-07-12	Αναστολεις πρωτεασωματος
CY2019009I2 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
EP2305306A4 (en)	2012-08-29	NEURO INVASION INHIBITOR
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0810365A2 (pt)	2014-10-29	Inibidores de mlc-1 de indol 7-substituído
SMT201600081B (it)	2016-04-29	Inibitore di bromodominio di benzodiazepina
BRPI0807547A2 (pt)	2014-06-17	Inibidores de aspartil protease hetercíclicos
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
BRPI0918564A2 (pt)	2015-12-01	inibidores
ATE522535T1 (de)	2011-09-15	Pyrrolotriazin-kinasehemmer
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0806898A2 (pt)	2015-07-14	Inibidores de mek
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
BRPI0919818A2 (pt)	2019-09-24	inibidores de seprase seletivos
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
EP2435048A4 (en)	2013-07-10	RADIOACTIVELY MARKED PDE10 HEMMER
BRPI0716198A2 (pt)	2013-11-12	Pirrolo-isoquinolinas como inibidores de cinase
EP2162436A4 (en)	2010-08-04	NEW CASE OF RENININHIBITORS

Legal Events

Date	Code	Title	Description
2015-06-09	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2015-09-08	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]